AbbVie joins US government pilot to test drug discount rebates

By Reuters News

Oct 2 (Reuters) - US drugmaker AbbVie ABBV.N said on Friday it would participate in a US government pilot program aimed at testing a new rebate system for discounted medicines.

Here are some details:

  • The pilot will begin on January 1, 2027, under the government's 340B program, which helps hospitals and clinics serving low-income patients buy medicines at a discount.

  • Under the new model, eligible healthcare providers will submit claims through a platform called Beacon to obtain 340B pricing on AbbVie's cancer drug Imbruvica, irritable bowel syndrome treatment Linzess and antipsychotic drug Vraylar.

  • AbbVie said it would provide healthcare groups with free access to the system, as well as customer service and special assistance for providers facing operational difficulties.

  • The rebate test will help improve pricing transparency and prevent duplicate discounts as new Medicare-negotiated drug prices take effect, the company said.

  • AbbVie said it plans to work closely with federal health regulators and healthcare providers throughout the rollout.

  • Besides AbbVie, Amgen AMGN.O, AstraZeneca AZN.L, Pfizer PFE.N and Bristol Myers Squibb BMY.N are among the companies approved for the federal pilot.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.